Indevus Sanctura XR To Begin Phase III Trials “Shortly”
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm targets second half of 2006 for NDA submission for the extended-release formulation of the overactive bladder treatment. Sanctura maintains 3% share of new prescriptions in the quarter despite heavy promotion from competitors.
You may also be interested in...
Sanctura XR Could Quench Indevus’ Thirst For Once-Daily Incontinence Therapy
Results from the first of two Phase III trials of trospium extended-release report 8.7% incidence of dry mouth, compared to 20.1% for twice-daily Sanctura.
Sanctura XR Could Quench Indevus’ Thirst For Once-Daily Incontinence Therapy
Results from the first of two Phase III trials of trospium extended-release report 8.7% incidence of dry mouth, compared to 20.1% for twice-daily Sanctura.
Sanctura Co-Promotion Deal
Esprit Pharma has become Indevus' new co-promotion partner for Sanctura (trospium), after acquiring marketing rights for the overactive bladder agent from Pliva